Blood Cell Count Ratios Predict Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Treated With First-Line Immune Checkpoint Inhibitors
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: First-line ICI-based therapies are commonplace in mRCC and frequency of irAEs is high. Although prognostication based on irAEs has been demonstrated, prediction of irAE occurrence in mRCC remains a challenge. Early identification of high-risk patients would enable personalized monitoring, earlier detection of irAEs, and more proactive toxicity management. We investigated the role of baseline blood cell count ratios to predict grade ≥2 irAEs with first-line ICI-based therapies in mRCC. PATIENTS AND METHODS: We used the City of Hope national database to retrospectively identify mRCC patients treated with first-line ICI-based therapies from September 2015 to September 2025. Baseline patient demographics and first-line ICI-based regimen were collected. We stratified baseline blood cell ratios: neutrophil-to-eosinophil ratio (NER), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune inflammation index (SII) using recursive partitioning and evaluated their association with occurrence of grade ≥2 irAEs. RESULTS: A total of 198 patients with mRCC were treated with first-line ICI-based therapy, of which 5 were excluded due to insufficient data. Of the 193 evaluable patients, the median age was 64, 100 patients (51.8%) received ICI-ICI and 93 patients (48.2%) received ICI-TKI. Grade ≥2 irAEs were observed in 57 patients (29.5%) and the most common was ALT/AST elevations in 18 patients (9.3%). All baseline blood cell ratios predicted occurrence of grade ≥2 irAEs in separate multivariable logistic regression analyses for each marker, with SII and PLR emerging as subgroup-specific risk factors in the ICI-ICI and ICI-TKI cohorts, respectively. CONCLUSION: Our findings support a novel role for these baseline blood cell ratios as factors associated with grade ≥2 irAEs in mRCC. These findings are hypothesis-generating and warrant prospective validation in larger patient populations.
Source: The Oncologist
Authors: Rahul Winayak, Kaela Makins, Xiaochen Li, Nicholas J Salgia, Ali Moradi, Vitor Abreu de Goes, Salvador Jaime-Casas, Koral U Shah, Miguel Zugman, Regina Barragan-Carrillo, Jadon C Fann, George Zhang, Benjamin Mercier, Yu Jun Li, Daniela V Castro, Hedyeh Ebrahimi, Nazli Dizman, JoAnn Hsu, Abhishek Tripathi, Alexander Chehrazi-Raffle, Tanya Dorff, Sumanta Kumar Pal
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,852
OpenAlex ID: W7233224607
